{"title":"The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review.","authors":"Dana Kaminski, Justin P Reinert","doi":"10.1177/10600280231205645","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The objective of this systematic review is to determine the tolerability and safety of psilocybin in a variety of psychiatric and substance-dependence conditions.</p><p><strong>Data sources: </strong>A systematic review was conducted using Embase, PubMed, Cochrane Central, and Web of Science through September 2023 using the following terminology: \"psilocybin\" AND \"mental-disease\" OR \"substance-dependence\" AND \"disease-therapy,\" in addition to other synonymous key words.</p><p><strong>Study selection and data extraction: </strong>Literature reporting acute effects and safety data following the use of psilocybin as the pharmacologic intervention in a clinical trial in adult patients with a psychiatric or substance-dependence condition were included. Following the application of inclusion and exclusion criteria, 16 studies were ultimately included in this review.</p><p><strong>Data synthesis: </strong>The most common treatment-emergent adverse effects reported were transient nausea and headache. Transient anxiety was reported as a frequent psychiatric effect, and 3 participants received a benzodiazepine for refractory anxiety during the psilocybin session. Psilocybin demonstrated modest increases in blood pressure and heart rate, and 1 participant received an antihypertensive for sustained hypertension during the psilocybin session. No cases of psilocybin-induced psychosis or Hallucinogen Persisting Perception Disorder were reported.</p><p><strong>Relevance to patient care and clinical practice: </strong>Treatment resistance remains a concern for psychiatric patients and novel therapies are needed to help alleviate the burden of morbidity and mortality. Psilocybin demonstrates promising acute and long-term safety that may allow for its use in psychiatric or substance-dependence conditions as an alternative to standards of care or in treatment-resistant patients.</p><p><strong>Conclusions: </strong>Psilocybin has demonstrated tolerability and safety in recent literature that has investigated its therapeutic potential in a variety of psychiatric or substance-dependence conditions.</p>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10600280231205645","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/30 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: The objective of this systematic review is to determine the tolerability and safety of psilocybin in a variety of psychiatric and substance-dependence conditions.
Data sources: A systematic review was conducted using Embase, PubMed, Cochrane Central, and Web of Science through September 2023 using the following terminology: "psilocybin" AND "mental-disease" OR "substance-dependence" AND "disease-therapy," in addition to other synonymous key words.
Study selection and data extraction: Literature reporting acute effects and safety data following the use of psilocybin as the pharmacologic intervention in a clinical trial in adult patients with a psychiatric or substance-dependence condition were included. Following the application of inclusion and exclusion criteria, 16 studies were ultimately included in this review.
Data synthesis: The most common treatment-emergent adverse effects reported were transient nausea and headache. Transient anxiety was reported as a frequent psychiatric effect, and 3 participants received a benzodiazepine for refractory anxiety during the psilocybin session. Psilocybin demonstrated modest increases in blood pressure and heart rate, and 1 participant received an antihypertensive for sustained hypertension during the psilocybin session. No cases of psilocybin-induced psychosis or Hallucinogen Persisting Perception Disorder were reported.
Relevance to patient care and clinical practice: Treatment resistance remains a concern for psychiatric patients and novel therapies are needed to help alleviate the burden of morbidity and mortality. Psilocybin demonstrates promising acute and long-term safety that may allow for its use in psychiatric or substance-dependence conditions as an alternative to standards of care or in treatment-resistant patients.
Conclusions: Psilocybin has demonstrated tolerability and safety in recent literature that has investigated its therapeutic potential in a variety of psychiatric or substance-dependence conditions.
目的:本系统综述的目的是确定裸盖菇素在各种精神和物质依赖条件下的耐受性和安全性。数据来源:截至2023年9月,使用Embase、PubMed、Cochrane Central和Web of Science进行了一项系统综述,使用了以下术语:“裸盖菇素”和“精神疾病”或“物质依赖性”和“疾病治疗”,以及其他同义关键词。研究选择和数据提取:包括报告在一项针对患有精神或物质依赖性疾病的成年患者的临床试验中使用裸盖菇素作为药物干预后的急性效应和安全性数据的文献。在应用纳入和排除标准后,本综述最终纳入了16项研究。数据综合:报告的最常见的治疗突发不良反应是短暂的恶心和头痛。据报道,短暂性焦虑是一种常见的精神影响,3名参与者在裸盖菇素治疗期间接受了苯二氮卓类药物治疗顽固性焦虑。Psilocybin显示血压和心率适度升高,1名参与者在裸盖菇素治疗期间因持续高血压接受了抗高血压药物治疗。没有裸盖菇素引起的精神病或幻觉原持续性感知障碍的病例报告。与患者护理和临床实践的相关性:治疗耐药性仍然是精神病患者关注的问题,需要新的疗法来帮助减轻发病率和死亡率的负担。Psilocybin显示出良好的急性和长期安全性,可用于精神病或物质依赖性疾病,作为护理标准或治疗耐药患者的替代品。结论:Psilocybin在最近的文献中证明了其耐受性和安全性,这些文献研究了其在各种精神或物质依赖性条件下的治疗潜力。